Compare AbbVie Inc (ABBV) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Lockheed Martin Corporation — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while Lockheed Martin Corporation trades at $530.6 (market cap $123.44B). The key difference: AbbVie Inc is far larger — about 3.6× Lockheed Martin Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | LMT | |
|---|---|---|
Market Cap | $449.91B | $123.44B |
Sector | Health | Industrials |
52-Week High | $261.07 | $676.70 |
52-Week Low | $184.85 | $410.74 |
Enterprise Value | $513.38B | $142.24B |
Dividend Yield | 2.72% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Lockheed Martin (LMT) trades at $535.38, down 1.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $627.50. Recent financials show revenue growth to $75.05B in 2025, though net income margin declined to 6.38%. The company announced a $3.45B acquisition of Ultra Maritime to expand naval defense capabilities, and a dividend of $3.45 is scheduled for payment in June 2026.
LMT offers stability through government contracts and dividend growth, but faces risks from execution on recent acquisitions and margin pressure. Analyst sentiment is positive with 57% buy ratings, yet recent earnings misses and rising debt levels warrant caution. The stock presents a long-term opportunity in defense, balanced by near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
